Do analysts recommend LTY or APS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liberty Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, LTY or APS?

Liberty Biopharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liberty Biopharma N/A N/A N/A -C$0.16 N/A Aptose Biosciences N/A N/A -C$154.69M -C$10.41 N/A

Is LTY or APS more profitable?

Aptose Biosciences' return on equity of 115.24% beat Liberty Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Liberty Biopharma N/A N/A N/A Aptose Biosciences N/A 115.24% -136.29%

Do analysts recommend ACST or APS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acasti Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer REUN or APS?

Given Reunion Neuroscience's higher probable upside, analysts plainly believe Reunion Neuroscience is more favorable than Aptose Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reunion Neuroscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is REUN or APS more profitable?

Aptose Biosciences' return on equity of 115.24% beat Reunion Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Reunion Neuroscience N/A -86.35% -26.50% Aptose Biosciences N/A 115.24% -136.29%

Do analysts prefer NEPT or APS?

Given Neptune Wellness Solutions' higher probable upside, equities analysts plainly believe Neptune Wellness Solutions is more favorable than Aptose Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neptune Wellness Solutions 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NEPT or APS more profitable?

Aptose Biosciences' return on equity of 115.24% beat Neptune Wellness Solutions' return on equity. Company Net Margins Return on Equity Return on Assets Neptune Wellness Solutions N/A N/A N/A Aptose Biosciences N/A 115.24% -136.29%

Do analysts rate ATE or APS?

Given Antibe Therapeutics' higher probable upside, equities analysts clearly believe Antibe Therapeutics is more favorable than Aptose Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Antibe Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aptose Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATE or APS more profitable?

Aptose Biosciences' return on equity of 115.24% beat Antibe Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Antibe Therapeutics N/A -52.72% -19.13% Aptose Biosciences N/A 115.24% -136.29%

Aptose Biosciences (APS) Competitors

C$2.19 0.00 (0.00%)

As of 06/12/2026 01:03 PM Eastern

Compare

APS vs. LTY, ACST, REUN, NEPT, and ATE

Should you buy Aptose Biosciences stock or one of its competitors? MarketBeat compares Aptose Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptose Biosciences include Liberty Biopharma (LTY), Acasti Pharma (ACST), Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), and Antibe Therapeutics (ATE). These companies are all part of the "biotechnology" industry.

How does Aptose Biosciences compare to Liberty Biopharma?

Liberty Biopharma (CVE:LTY) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Liberty Biopharma's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company	Overall Sentiment
Liberty Biopharma	Neutral
Aptose Biosciences	Neutral

Aptose Biosciences' return on equity of 115.24% beat Liberty Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liberty Biopharma	N/A	N/A	N/A
Aptose Biosciences	N/A	115.24%	-136.29%

Liberty Biopharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liberty Biopharma	N/A	N/A	N/A	-C$0.16	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liberty Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.0% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Aptose Biosciences beats Liberty Biopharma on 5 of the 7 factors compared between the two stocks.

How does Aptose Biosciences compare to Acasti Pharma?

Acasti Pharma (CVE:ACST) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Aptose Biosciences has a net margin of 0.00% compared to Acasti Pharma's net margin of -455.58%. Aptose Biosciences' return on equity of 115.24% beat Acasti Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acasti Pharma	-455.58%	-67.58%	-8.25%
Aptose Biosciences	N/A	115.24%	-136.29%

0.1% of Acasti Pharma shares are owned by institutional investors. Comparatively, 0.0% of Aptose Biosciences shares are owned by institutional investors. 20.3% of Acasti Pharma shares are owned by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Acasti Pharma has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Aptose Biosciences has a beta of -1.378818, suggesting that its stock price is 238% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acasti Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acasti Pharma has higher revenue and earnings than Aptose Biosciences. Acasti Pharma is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acasti Pharma	C$2.71M	6.71	-C$10.54M	-C$0.48	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

In the previous week, Acasti Pharma's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company	Overall Sentiment
Acasti Pharma	Neutral
Aptose Biosciences	Neutral

Summary

Acasti Pharma beats Aptose Biosciences on 7 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Reunion Neuroscience?

Reunion Neuroscience (TSE:REUN) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Reunion Neuroscience has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Reunion Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reunion Neuroscience	C$4.86M	0.00	-C$38.10M	-C$3.30	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

In the previous week, Reunion Neuroscience's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company	Overall Sentiment
Reunion Neuroscience	Neutral
Aptose Biosciences	Neutral

Aptose Biosciences' return on equity of 115.24% beat Reunion Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reunion Neuroscience	N/A	-86.35%	-26.50%
Aptose Biosciences	N/A	115.24%	-136.29%

Given Reunion Neuroscience's higher probable upside, analysts plainly believe Reunion Neuroscience is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reunion Neuroscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

50.7% of Reunion Neuroscience shares are held by institutional investors. Comparatively, 0.0% of Aptose Biosciences shares are held by institutional investors. 34.4% of Reunion Neuroscience shares are held by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Reunion Neuroscience has a beta of 4.2, suggesting that its share price is 320% more volatile than the broader market. Comparatively, Aptose Biosciences has a beta of -1.378818, suggesting that its share price is 238% less volatile than the broader market.

Summary

Reunion Neuroscience beats Aptose Biosciences on 8 of the 11 factors compared between the two stocks.

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Neptune Wellness Solutions (TSE:NEPT) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

Aptose Biosciences has lower revenue, but higher earnings than Neptune Wellness Solutions. Aptose Biosciences is trading at a lower price-to-earnings ratio than Neptune Wellness Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neptune Wellness Solutions	C$48.80M	0.00	-C$192.95M	-C$24.16	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

0.0% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Given Neptune Wellness Solutions' higher probable upside, equities analysts plainly believe Neptune Wellness Solutions is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neptune Wellness Solutions	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Neptune Wellness Solutions' average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company	Overall Sentiment
Neptune Wellness Solutions	Neutral
Aptose Biosciences	Neutral

Aptose Biosciences' return on equity of 115.24% beat Neptune Wellness Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neptune Wellness Solutions	N/A	N/A	N/A
Aptose Biosciences	N/A	115.24%	-136.29%

Summary

Aptose Biosciences beats Neptune Wellness Solutions on 6 of the 10 factors compared between the two stocks.

How does Aptose Biosciences compare to Antibe Therapeutics?

Antibe Therapeutics (TSE:ATE) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Aptose Biosciences' return on equity of 115.24% beat Antibe Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Antibe Therapeutics	N/A	-52.72%	-19.13%
Aptose Biosciences	N/A	115.24%	-136.29%

Antibe Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Aptose Biosciences has a beta of -1.378818, meaning that its share price is 238% less volatile than the broader market.

Antibe Therapeutics has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Antibe Therapeutics	C$9.71M	0.00	-C$18.24M	-C$0.35	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$10.41	N/A

Given Antibe Therapeutics' higher probable upside, equities analysts clearly believe Antibe Therapeutics is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Antibe Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

0.0% of Aptose Biosciences shares are held by institutional investors. 7.9% of Antibe Therapeutics shares are held by insiders. Comparatively, 17.1% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Antibe Therapeutics' average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company	Overall Sentiment
Antibe Therapeutics	Neutral
Aptose Biosciences	Neutral

Summary

Antibe Therapeutics beats Aptose Biosciences on 6 of the 11 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APS vs. The Competition

Export

Metric	Aptose Biosciences	Biotechnology Industry	Medical Sector	TSE Exchange
Market Cap	C$5.59M	C$445.46M	C$6.52B	C$12.19B
Dividend Yield	0.39%	3.88%	2.67%	6.19%
P/E Ratio	-0.21	3.18	24.00	36.94
Price / Sales	N/A	6,530.52	516.42	10.45
Price / Cash	1.60	13.13	27.48	82.29
Price / Book	-0.16	90.74	10.74	4.47
Net Income	-C$154.69M	-C$96.07M	C$3.57B	C$299.09M
7 Day Performance	-0.45%	0.01%	0.58%	0.65%
1 Month Performance	-6.01%	-0.31%	1.48%	-0.08%
1 Year Performance	-7.98%	56.17%	25.41%	41.90%

Aptose Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APS Aptose Biosciences	N/A	C$2.19 flat	N/A	-8.0%	C$5.59M	N/A	N/A	31
LTY Liberty Biopharma	N/A	C$2.00 +∞	N/A	+0.0%	C$21.54M	N/A	N/A	N/A	Gap Up
ACST Acasti Pharma	N/A	C$0.58 +1.8%	N/A	+0.0%	C$18.19M	C$2.71M	N/A	32
REUN Reunion Neuroscience	N/A	N/A	N/A	N/A	C$16.64M	C$4.86M	N/A	190	Gap Down
NEPT Neptune Wellness Solutions	N/A	N/A	N/A	N/A	C$15.73M	C$48.80M	N/A	130	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:APS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptose Biosciences (APS) Competitors

APS vs. LTY, ACST, REUN, NEPT, and ATE

How does Aptose Biosciences compare to Liberty Biopharma?

Summary

How does Aptose Biosciences compare to Acasti Pharma?

Summary

How does Aptose Biosciences compare to Reunion Neuroscience?

Summary

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Summary

How does Aptose Biosciences compare to Antibe Therapeutics?

Summary

Media Sentiment Over Time

APS vs. The Competition

Aptose Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptose Biosciences (APS) Competitors

APS vs. LTY, ACST, REUN, NEPT, and ATE

How does Aptose Biosciences compare to Liberty Biopharma?

Does the media refer more to LTY or APS?

Is LTY or APS more profitable?

Which has better earnings and valuation, LTY or APS?

Do analysts recommend LTY or APS?

Do insiders & institutionals hold more shares of LTY or APS?

Summary

How does Aptose Biosciences compare to Acasti Pharma?

Is ACST or APS more profitable?

Do insiders and institutionals hold more shares of ACST or APS?

Which has more volatility & risk, ACST or APS?

Do analysts recommend ACST or APS?

Which has better valuation and earnings, ACST or APS?

Does the media favor ACST or APS?

Summary

How does Aptose Biosciences compare to Reunion Neuroscience?

Which has higher earnings and valuation, REUN or APS?

Does the media refer more to REUN or APS?

Is REUN or APS more profitable?

Do analysts prefer REUN or APS?

Do institutionals and insiders believe in REUN or APS?

Which has more volatility and risk, REUN or APS?

Summary

How does Aptose Biosciences compare to Neptune Wellness Solutions?

Which has stronger earnings and valuation, NEPT or APS?

Do institutionals & insiders hold more shares of NEPT or APS?

Do analysts prefer NEPT or APS?

Does the media prefer NEPT or APS?

Is NEPT or APS more profitable?

Summary

How does Aptose Biosciences compare to Antibe Therapeutics?

Is ATE or APS more profitable?

Which has more risk & volatility, ATE or APS?

Which has stronger valuation & earnings, ATE or APS?

Do analysts rate ATE or APS?

Do institutionals and insiders hold more shares of ATE or APS?

Does the media refer more to ATE or APS?

Summary

Media Sentiment Over Time

APS vs. The Competition

Aptose Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools